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Background: Coronary heart disease (CHD) is a major cause of morbidity and mortality in post menopausal
women. There is strong evidence suggesting that estrogen deficiency increases cardiovascular risk. For years
hormone replacement therapy (HRT) was thought to be beneficial for the prevention of CHD in
postmenopausal women. Observational studies consistently concluded that HRT reduced overall mortality
from CHD events in postmenopausal women. A large randomized control trial, called the Women’s Health
Initiative (WHI), was later conducted and did not concur with these findings. This created much controversy
within the medical community with regard to benefits and risks associated with HRT. However, further
analysis of the WHI did show that there was reduced overall mortality in women using HRT aged 50-59. The
literature review conducted was to examine if there was in fact a benefit of HRT versus placebo for
postmenopausal women to reduce mortality caused from CHD.
Methods: Exhaustive search of available medical literature using Medline-Ovid, CINAHL, and JAMA was
conducted with the following terms: hormone replacement therapy, postmenopause, cardiovascular disease,
and mortality.
Results: A total of 4 studies were appraised. One study was a randomized control trial and the remaining three
studies were observational studies. The randomized control study initially showed an increased mortality rate
from CHD among menopausal women using HRT versus placebo users, but after further evaluation did show
a decreased mortality rate amongst women aged 50-59 using HRT. Observational studies showed an overall
decreased mortality among women using HRT versus non-HRT users caused by CHD.
Conclusion: HRT was initially thought to carry an added benefit of decreasing CHD events in
postmenopausal women, but was found in randomized control trials to carry an increased risk for older
women. Based on the studies evaluated, it can be concluded that women who are symptomatic from
menopause and do not have a history of coronary heart disease or breast cancer would benefit from HRT as
soon as menopause starts and experience reduced mortality from CHD events if taken for 2-3 years or
possibly more.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
First Advisor
James Ferguson PA-C, MPH
Second Advisor
Annjanette Sommers MS, PAC
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/222
Third Advisor
Rob Rosenow PharmD, OD
Keywords
Hormone Replacement Therapy, Postmenopause, Cardiovascular Disease, Mortality
Subject Categories
Medicine and Health Sciences
Rights
Terms of use for work posted in CommonKnowledge.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/222
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/222
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
1 
 
 
Mortality Associated With Coronary Heart Disease in Postmenopausal Women 
Using Hormone Replacement Therapy 
 
 
 
 
 
 
 
 
 
 
Brooke Elyssa Arias 
 
 
 
 
 
 
 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the  
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR  
For the Masters of Science Degree, August 14, 2010 
 
Faculty Advisor: James Ferguson, PA-C 
Clinical Graduate Project Coordinators: Annjanette Sommers MS, PAC & Rob Rosenow 
PharmD, OD  
 
 
 
2 
 
Biography 
 
[Redacted for privacy] 
  
3 
 
 
Abstract   
 
Background: Coronary heart disease (CHD) is a major cause of morbidity and mortality 
in post menopausal women. There is strong evidence suggesting that estrogen deficiency 
increases cardiovascular risk. For years hormone replacement therapy (HRT) was thought 
to be beneficial for the prevention of CHD in postmenopausal women. Observational 
studies consistently concluded that HRT reduced overall mortality from CHD events in 
postmenopausal women. A large randomized control trial, called the Women’s Health 
Initiative (WHI), was later conducted and did not concur with these findings. This created 
much controversy within the medical community with regard to benefits and risks 
associated with HRT. However, further analysis of the WHI did show that there was 
reduced overall mortality in women using HRT aged 50-59. The literature review 
conducted was to examine if there was in fact a benefit of HRT versus placebo for 
postmenopausal women to reduce mortality caused from CHD.  
Methods:  Exhaustive search of available medical literature using Medline-Ovid, 
CINAHL, and JAMA was conducted with the following terms: hormone replacement 
therapy, postmenopause, cardiovascular disease, and mortality.  
Results:  A total of 4 studies were appraised. One study was a randomized control trial 
and the remaining three studies were observational studies. The randomized control study 
initially showed an increased mortality rate from CHD among menopausal women using 
HRT versus placebo users, but after further evaluation did show a decreased mortality 
rate amongst women aged 50-59 using HRT. Observational studies showed an overall 
decreased mortality among women using HRT versus non-HRT users caused by CHD.  
Conclusion: HRT was initially thought to carry an added benefit of decreasing CHD 
events in postmenopausal women, but was found in randomized control trials to carry an 
increased risk for older women. Based on the studies evaluated, it can be concluded that 
women who are symptomatic from menopause and do not have a history of coronary 
heart disease or breast cancer would benefit from HRT as soon as menopause starts and 
experience reduced mortality from CHD events if taken for 2-3 years or possibly more.   
Keywords:  Hormone Replacement Therapy, Postmenopause, Cardiovascular Disease, 
Mortality 
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Mortality Associated With Coronary Heart Disease in Postmenopausal Women 
Using Hormone Replacement Therapy 
 
BACKGROUND 
Coronary heart disease (CHD) is a major cause of morbidity and mortality in 
women.1 Most cardiovascular disease in women occurs in the postmenopausal phase of 
life and it appears that a protective factor or array of factors operative in premenopause 
may become inactive after menopause.2 Much of the current thinking hypothesizes that 
the protective factor present before menopause but not after menopause is estrogen.2 
There is strong evidence suggesting that estrogen deficiency, which occurs after 
menopause in women, increases cardiovascular risk.3  
Hot flashes, the most common vasomotor symptom, are experienced at some time 
by most postmenopausal women.4 Most women experience hot flashes for the several 
years around the final menstrual period.5 However, hot flashes can persist for decades.5 
Vasomotor symptoms are viewed largely as a symptom affecting quality of life and are 
the leading reason women seek menopause-related health care.4 Unfortunately, women 
who are experiencing difficulties from menopause and seeking HRT are faced with a 
decision which can ultimately resemble a life or death choice.  
For years hormone replacement therapy (HRT) was considered to be beneficial 
for the prevention of CHD in postmenopausal women. HRT was not licensed for use in 
the prevention of CHD, but it was considered an additional benefit when the treatment 
was given for the relief of menopausal symptoms or for the prevention of 
postmenopausal osteoporosis.6 To test the risks and benefits, the US government 
sponsored a large study called the Women’s Health Initiative (WHI) that enrolled 
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postmenopausal women, regardless of indication for HRT, to determine if CHD could be 
prevented. The results of this study were prematurely released before the results could be 
properly evaluated which created a negative attitude about hormonal replacement therapy 
within the medical community. Many misconceptions and misperceptions played roles in 
this complicated situation: some were scientific; others were cultural or social.7 
In the assessment of risks and benefits of HRT, observational studies and clinical 
trials have yielded apparently conflicting results.8 The observational studies of women 
with and without existing coronary heart disease (CHD) showed that the use of 
postmenopausal hormone therapy is associated with a reduced risk of CHD events.9 In 
contrast, clinical trials have shown no benefit and some have shown an increased risk of 
CHD.10 This confusion is something that postmenopausal patients and their physicians 
face daily and this is particularly true in the cardiovascular field.  
Many cardiologists may feel that they do not need to consider HRT as they have 
other strategies for preventing CHD in women.6 Some feel that attention to lifestyle 
factors such as diet, physical exercise and smoking will reduce CHD incidence. However, 
most women increase their body weight and body weight distribution (BMI) during the 
first year since menopause due to the hormonal changes.11 Similarly, control of blood 
pressure and diabetes are also important preventive measures. Yet, changes in body 
weight and insulin resistance associated with postmenopausal estrogen deficiency may 
also contribute to the increase in blood pressure.11 Risk factor stratification seems straight 
forward but does not seem to be the only tools needed to prevent a postmenopausal 
woman from the risk of having a CHD event that may result in death. As coronary heart 
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disease remains the biggest threat of mortality in women,1, specifically postmenopausal 
women, no rock should be left unturned in reducing the possibility of death.  
The term “menopause” denotes the final cessation of menstruation, either as a 
normal part of aging or as the result of surgical removal of both ovaries. In a broader 
sense, as the term is commonly used, it denotes a 1-to-3 year period during which a 
woman adjusts to a diminishing and then absent menstrual flow and the physiological 
changes that may be associated— hot flashes, night sweats, and vaginal dryness. 
Postmenopause — Stage +1 (early) is defined as the first five years after the final 
menstrual period. It is characterized by further and complete dampening of ovarian 
function and accelerated bone loss; many women in this stage continue to have hot 
flashes. Stage +2 (late) begins five years after the final menstrual period and ends with 
death.12 
HRT is classified as the use of estrogen or estrogen and progestin combination for 
reasons other than contraception.9,13,14 There is no distinction between type and dosage or 
specific regimens of HRT that was defined in most studies. Estrogen and progestin use is 
specific to women with an intact uterus and the estrogen only option is reserved for 
women who did not have an intact uterus.9,13,14   
CHD is defined as sudden death, acute myocardial infarction, heart failure, aortic 
aneurysm and pulmonary embolism, but does not include stroke.9,13 Mortality due to 
coronary heart disease (CHD) included sudden death and death by MI,14,15,and was 
obtained by ICD-9 codes of 401-414 or 420-447 or autopsy for evaluation of mortality 
causes.  
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Purpose of study 
Due to the confusion regarding the risks and benefits of HRT in postmenopausal 
women that was created when the WHI was published, it only seemed appropriate to 
investigate further. The purpose of this review was to systematically evaluate the 
literature that examined if there was value in hormonal replacement therapy to help 
protect against risk of cardiovascular events relating to mortality in postmenopausal 
women. The best research would attempt to control for all potential variables and recruit 
enough participants to produce significant statistical information to be utilized in clinical 
practice. Postmenopausal women are faced with a choice to allow for a better quality of 
life when becoming symptomatic from menopause and should not be faced with a 
decision that could ultimately increase the likelihood of increased mortality due to 
coronary heart disease. 
Clinical Question 
The question of a postmenopausal woman suffering from menopausal symptoms 
and attempting to determine the risks and benefits of HRT with regard to coronary heart 
disease represents a common challenge in medicine.  Providers who consult available 
literature find conflicting information about the risks and benefits. Due to coronary heart 
disease being the leading cause of death,1,in postmenopausal women, and providers being 
responsible to counsel patients about all aspects of decreasing the possibility of mortality, 
it is imperative to be abreast of all available options for improving the odds of surviving 
CHD. Does HRT in postmenopausal women reduce mortality from CHD? 
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METHODS  
Search Strategy 
An exhaustive literature search using Medline-OVID, CINAHL, and JAMA, was 
conducted with the following terms used: hormone replacement therapy, postmenopause, 
cardiovascular disease, and mortality. The systematic review examines research that 
contributes to the risks and benefits of HRT use in postmenopausal women, particularly 
with regard to mortality associated with coronary heart disease.  
Eligibility Criteria 
Studies that evaluated postmenopausal women taking HRT compared to those 
who were either taking a placebo or no HRT at all while assessing mortality directly 
linked to CHD were used. Studies could be used that included perimenopausal women, 
but only results that pertained to postmenopausal women were used. All studies were 
limited to the English language. Only studies that were published in the last 10 years 
comparing HRT use versus placebo in postmenopausal women are included. Cohort and 
case studies, both prospective and retrospective, as well as a randomized control study 
are included. There were more randomized control studies available, but these were not 
conducted in the past 10 years.  
 Excluded studies were meta-analysis studies, studies that were greater than 10 
years old for discussion other than background information. Any studies that did not 
correlate mortality with HRT were excluded. Personal view articles were limited to 
background information.  
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RESULTS 
The electronic databases search identified 30 articles using the search criteria 
listed above. After the eligibility criterions were applied, a total of 4 articles were 
appraised (see Table 1). There is one randomized control trial and three retrospective 
cohort studies being evaluated. Overall, the studies addressed several different aspects of 
mortality due to CHD. Some studies looked at the incidence of myocardial infarction and 
death in relation to use of hormone replacement. Other studies investigated the long-term 
effects of HRT in the mortality of cardiovascular events.  
In the randomized control trial with 16 608 postmenopausal women participants 
published in JAMA, Rossouw et al,13, reported in 2002 that the WHI finding that 
estrogen plus progestin does not confer benefit for preventing CHD among women with a 
uterus. Postmenopausal women aged 50-79 years old were placed in sets of clinical trials 
(2 of which were postmenopausal hormone use) and various observation studies. A total 
of 16 608 women participants were selected for postmenopausal hormone use if she 
experienced no vaginal bleeding for 6 months or specifically had no vaginal bleeding for 
12 months if aged 50-54 and had an intact uterus. Women were selected regardless of 
symptoms from menopause and were excluded if she had any competing risks including a 
medical condition with a predicted survival of <3 years, other prior cancer within the last 
10 years, low hematocrits and platelet counts or dementia and alcoholism. Participants 
were considered to overall be healthy, as 7.7% reported having a history of prior 
cardiovascular disease.13  
Initially, the design allowed the 16 608 participants with a uterus to be 
randomized to receive unopposed estrogen, estrogen plus progestin, or placebo. The 
protocol was later changed in the study to only allow estrogen plus progestin and 
14 
 
placebo. The 331 women previously randomized to unopposed estrogen were unblinded 
and reassigned to 1 daily tablet containing conjugated equine estrogen (CEE), 0.625mg, 
and medroxyprogesterone acetate (MPA), 2.5mg. Clinical outcomes by randomization 
assignment were divided into women who received estrogen + progestin (n=8506) and 
women who received a placebo (n=8102). These two groups of women had a follow up 
time of 62.2 months if taking estrogen + progestin and 61.2 months if taking placebo.13  
Combined estrogen and progestin was provided in one daily tablet containing 
conjugated equine estrogen (CEE) 0.625mg, and medroxyprogesterone acetate (MPA) 
2.5mg. During the trial, some flexibility of the dosages of both estrogen and progestin 
was allowed to manage symptoms including breast tenderness and vaginal bleeding.  
Permanent discontinuation of study medication was required by protocol for women who 
developed breast cancer, endometrial pathological state, deep vein thrombosis, 
pulmonary embolism, malignant melanoma, triglyceride levels >1000 mg/dl, or who 
were prescribed medications from personal physicians that would interfere with treatment 
plans. Medications were temporarily discontinued in participants who had acute 
myocardial infarctions, stroke, fracture, or major injury involving hospitalization, surgery 
requiring anesthesia or any other severe illness in which hormone use was temporarily 
inappropriate.13    
Baseline characteristics for participants included age, race, previous hormone use, 
body mass index (BMI), past medical history (PMH) including: diabetes, hypertension, 
elevated cholesterol, statin use at baseline, aspirin use at baseline, and current smoking 
status. Of the total participants in both groups over 45% of the participants were aged 60-
69. Another characteristic was race, in which 84% participants claimed to be of white 
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ethnicity. The majority of women in both groups (~34%) were found to have a higher 
BMI of ≥30. Finally, it was noted that about 50% of the total participants claimed to have 
never smoked, but a similar proportion of about 40% did have a history of previous 
smoking use with the remaining 10% claiming current use. (see Table 2).13  
A total of 231 participants in the HRT group compared to 218 placebo 
participants died during the study. Of these women, 33 who were taking Estrogen + 
Progestin, had an outcome of CHD death compared to 26 women who were taking 
placebo (HR 1.18, CI 0.70-1.97). There were also more HRT users who suffered CHD 
events than placebo takers (HR 1.29, CI 1.02-1.63). (see Table 3). The trial was stopped 
early, after an average of 5.2 years of follow-up, because it was found that the health 
risks associated with estrogen plus progestin exceeded the benefits.13   
In 2007, a secondary analysis was performed again by Rossouw et al,9,of the 
complete WHI findings and explored whether the effects of hormone therapy on risk of 
cardiovascular disease vary by age or years since menopause. This secondary analysis 
improved statistical power by the use of techniques that allowed combining the trial data 
to examine trends in the effects of hormone therapy on CHD across categories of age and 
years since menopause. Baseline characteristics included in this study for the HRT versus 
placebo groups remained the same, but included years since menopause and vasomotor 
symptoms. Of the 8506 participants who took HRT, roughly 33% started therapy <10 
years since menopause in both groups. The majority of these women belonged to the age 
group of 50-59 (n=4092). Women who were of the age 60-69 (~45%) in both groups 
were also noted to be 10-19 years past menopause in the majority of this age category 
(~71%). (see Table 2).9 
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 In the secondary analysis, it was shown that in the all age categories, women who 
were taking HRT had an overall higher rate of CHD events compared to placebo users. It 
was found that overall mortality was lower in women aged 50-59 who were assigned to 
the HRT group versus placebo, but this trend reverses in all other age categories (HR 
0.69, CI 0.44-1.07). (see Table 4).9 
The first observational study,14,evaluated examined the incidence of myocardial 
infarction, cancer and death in relationship to use of hormone replacement therapy 
(HRT). This urban prospective study was collected by Hedblad et al,14,when a 
questionnaire was mailed to former participants that had previously been evaluated at The 
Section of Preventative Medicine, Department of Medicine at Malmӧ University 
Hospital in Sweden for high-risk cardiovascular disease. The evaluation included blood 
pressure recordings and blood sampling. A self-administered questionnaire was used to 
assess smoking habits, medical history, parity, menopause and use of HRT.14 
A total of 5862 women confirmed in the questionnaire that their menstruation has 
ceased or who used HRT because of menopausal problems. Of these women, a total of 
972 women were found to be taking HRT for menopausal symptoms, while 4890 women 
were not taking HRT. The questionnaire contained no further information regarding type, 
dose, duration, or compliance with treatment. Women with a history of breast (n=121) or 
endometrial cancer (n=20) were excluded, while those with other forms of cancer were 
included. Thus the study population consisted of 5721 women. Information on morbidity 
and mortality following health examination was obtained by record linkage with the 
national inpatient register and reviewed by ICD-9 code.14 
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Baseline characteristics included age, BMI, smoking habits, and education. The 
average age was roughly 54 years old and the majority (~70%) of women carried a BMI 
of <26 in both groups. Almost half of the women surveyed admitted to never smoking 
and were categorized into current and former smokers. There was no defined time line for 
how many years participants had been former smokers. Women who completed 
secondary education noted to be higher in the HRT group with 17% (n=164) reporting 
completion compared to 11.7% (n=557) of nonusers. (see Table 6).14  
A total of 202 women died in the 9 year follow-up and a total of 49 died from 
cardiovascular disease. Of these deaths, the cardiovascular mortality rate in HRT users 
was 0.36 (CI 0.08-1.08) and in non-users 1.10 (CI 0.78-1.41) per 1,000 person-years (p= 
0.686).  These results were with covariates of baseline characteristics and were not 
separated. (see Table 7).14 
An observational retrospective cohort study,15,with 1458 postmenopausal women 
aged 44-75 who had participated in several randomized, placebo-controlled, clinical trials 
were invited for a follow-up examination and questionnaire. These women had originally 
been part of studies that were assessing the efficacy of different estrogen plus progestin 
combinations given for 2-3 years for preventing postmenopausal bone loss. Stringent 
inclusion and exclusion criteria ensured that all women were healthy at entry to these 
trials without chronic disease, including CHD. None of the subjects took any medications 
to affect body composition or lipid metabolism for at least 6 months prior to 
randomization. If women had used HRT before the initial short-term period, or had taken 
HRT during her participation for less than 6 months, or if she had been using HRT for 
more than 3 months after participating in the initial studies, she was excluded.15  
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Baseline characteristics in the study were age, BMI, serum total cholesterol, 
serum triglycerides, fasting serum glucose, white blood cell count and current smoking 
status. Age at baseline in the HRT users (n=553) averaged 55.3 +/- 5.6 years compared to 
55.9 +/- 6.4 years in the placebo users (n=727). The BMI in this study was 24.9 +/- 3.9 
for HRT users (n=553) and 25.6 +/- 4.5 for non-users (n=727). There were roughly about 
50% of all participants in both groups that were noted to be current smokers. (see Table 
6).15 
The primary end-point of this study performed by Alexandersen et al,15,was all-
cause and cardiovascular death. A total of 174 women (13.6% of the cohort) died during 
the 10.9 years follow-up period. A total of 61 women died from cardiovascular events, 68 
of cancer, and 45 due to other causes of death. Specifically, 39 of these women died of 
CHD. Of these 39 women, 8 total were taking HRT and 31 were not (HR 0.47, CI 0.21-
1.03; p=0.062). These groups were not further classified into baseline characteristics. (see 
Table 7).15 
Lastly, another retrospective cohort study conducted by Shlipak et al,16,was 
performed with 114 724 women of age ≥55 years with confirmed myocardial infarction 
in the hospital in one of 1674 participating hospitals and evaluated in-hospital survival or 
mortality in women who were using or not using HRT. Women were limited to ≥ 55 as 
the study did not collect information on menopausal status. Presenting characteristics, 
treatment and clinical outcomes data was obtained by chart review. Patients were 
excluded if they were transferred to another hospital as information regarding their vital 
status was lacking.16 
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A total of 7353 women were found to be using HRT prior to hospitalization and a 
total of 107 371 were nonusers of HRT, but there was no record of past use or dose of 
current use. Of the 7353 women using HRT, overall 7% (n=514) faced overall mortality, 
while 16% (n=17 179) of the 107 371 nonuser faced overall mortality (OR 0.40, CI 0.36-
0.43). This is further broken down by age, with women aged >85 having the highest 
mortality rate compared to 3% of HRT users and 9% of non users in the age group 55-64. 
(see Table 7). 16 Adjustments were made for prior medical history, clinical characteristics, 
treatment received in-hospital, and likelihood of receiving HRT. Reduction in odds for 
mortality after adjustment varied from 28% to 46%, with associated being strongest for 
the youngest group of women (aged 55-64 years).16 
  At initial presentation, women who were hormone users had slightly higher 
systolic blood pressure and lower heart rates and were more likely to complain of chest 
discomfort than nonusers. Hormone users were more likely to be white and less likely to 
have a history of diabetes, heart failure, prior MI, and prior stroke than nonusers but were 
found to have hypercholesteremia and family history of premature coronary artery 
disease and to use tobacco. Lastly HRT users received more aggressive in-hospital care 
than women who were nonusers and were more likely to receive reperfusion therapy.16 
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DISCUSSION 
 
Hormone Replacement Therapy 
The studies that were reviewed resulted in very different outcomes. The results of 
the literature when evaluating for mortality from CHD events indicate that the benefits of 
HRT may outweigh the risks if treatment is given to younger woman. The risks may 
outweigh the benefits if treatment is started at a later age. Even the end results of the 
WHI study concluded that health consequences of hormone therapy may vary by distance 
from menopause, with no apparent increase in CHD risk for women close to menopause, 
and particularly high risks in women who are distant from menopause and have 
vasomotor symptoms.9 The study also stated that there was no reduced risk of CHD, but 
there was a total mortality reduction noted in women aged 50-59.9  
One study,15,suggested that a duration of 2-3 years of HRT may be beneficial to 
decrease mortality. In the end of this study, they conclude that short-term use of HRT in 
healthy postmenopausal women provides long-term cardiovascular benefits as indicated 
by a decreased all-cause and cardiovascular mortality rate and decelerated atherogenesis 
compared with non-users of HRT.15 There is still no concise optimal age at initiation of 
treatment or other studies to conclude the exact duration of HRT use.   
Overall, the studies did attract a large enough pool of participants to support good 
data. The follow-up time was appropriate in all the studies examined and was noted to be 
longer in the cohort studies. The risk of bias in the randomized control trial was high due 
to the fact that the women in the study were used for scientific research rather than for 
symptomatic treatment of hormonal menopausal symptoms. The WHI study attempted to 
enroll a diverse ethnic background of women, but most of the studies had more white 
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women enrolled than all the other ethnicities combined. In the observational studies 
(cohorts), women who were postmenopausal tended to be better educated and relatively 
healthier that took HRT compared to those that did not. HRT users also may have had 
more access to health care than non-users based off of educational completion. 
Confounding variables were of immense importance when trying to compare 
these studies. Some populations simply were not equal. Coronary heart disease is a multi 
factorial disease that is increased from multiple variables. Women who at screening had 
untreated hypertension, hyperlipidemia, or hyperglycemia were at times treated while 
participating in the studies. Attempting to separate all of these is impossible. BMI, 
smoking status and HRT type and duration were some confounders that were completely 
different in each study used.  
Study Limitations 
In the randomized control trial (WHI study13), the selection of postmenopausal 
women was for the age group of 50-79 years. The majority of women in this study were 
between 60-69 years old, which was older than most other studies. A woman was 
considered postmenopausal if she had experienced no vaginal bleeding for 6 months (12 
months for 50 to 54 year olds).13 Women were limited to an intact uterus and either 
placed on combined estrogen and progestin or placed on placebo.  
Initially, the design allowed women with a uterus to be randomized to receive 
unopposed estrogen, estrogen plus progestin, or placebo. The protocol was later changed 
in the WHI study 13to only estrogen plus progestin and placebo only. The 331 women 
previously randomized to unopposed estrogen were unblinded and reassigned to 1 daily 
tablet containing conjugated equine estrogen (CEE), 0.625mg, and medroxyprogesterone 
acetate (MPA), 2.5mg.13These women were not excluded from the overall results, 
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allowing variables in this specific population of women in the results section to be 
flawed. Only one drug regimen was used and during the trial some flexibility of the 
dosages of the estrogen plus progestin was allowed for women having side effects, as 
well as a temporary cessation of treatment, which in part may have skewed the overall 
results.  
Out of a total of 8506 women who were blinded to take the estrogen plus 
progestin 2899 (34.2%) were found to have a BMI >30 compared to the 2737 (34.0%) of 
the 8102 women that were taking the placebo.13 A larger population of women in this 
entire study carried a heavier BMI compared to other observational studies. Of these 
categories, 3362 women in the estrogen plus progestin group had formerly smoked, and 
880 women admitted to currently smoking.13These results were not separated in the 
results of mortality of CHD. Both obesity and smoking are known risk factors that 
increase the chances of mortality.  
Lastly, this study did not select women who were symptomatic with menopausal 
symptoms, which is generally the initiation of all hormone replacement therapy. In fact, 
women tended to be older, aged 60-69 and most were 10-19 years past menopause when 
therapy was started.9 This study did attempt to provide data on which to base treatment 
recommendations for healthy postmenopausal women with an intact uterus. This trial did 
not address the short-term risks and benefits of hormones given for the treatment of 
menopausal symptoms.13   
In the nine year cohort study implemented by Hedblad et al,14, in which subjects 
that had previously been evaluated in Sweden for high-risk cardiovascular disease were 
invited for a follow up questionnaire. Morbidity and mortality figures were obtained from 
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the National Board of Health and Welfare that identified participants and collected a 
diagnosis for proper identification of cause of death.14 Baseline characteristics also 
included age, BMI, and smoking habits to name a few. There was approximately 64.2% 
of 4,759 nonusers with a BMI of <26 compared to 74.7% of 962 HRT users, which is 
more conducive to believe that obesity did not play an extremely large role in this study 
with regards to mortality.14 Most women were also noted to be in their mid fifties, which 
is closer to menopause than the majority of the WHI participants were. This study also 
represented a large observation of postmenopausal women who never smoked. Of 4,759 
non-users, 47.5% never smoked, while 45.8% of 962 of the HRT users never smoked. 
There was no information on what time length was allowed for former smokers.14 
In the study conducted by Alexander et al,15,1458 postmenopausal women aged 
44 to 75 who had participated in randomized, placebo-controlled, clinical trials to 
investigate the impact of different HRT regimens given for either 2 or 3 years on 
postmenopausal bone loss. The study also used BMI and smoking status as baseline 
characteristics. The BMI in this study was 24.9 +/- 3.9 for HRT users and 25.6 +/- 4.5 for 
non-users.15This was much lower than the WHI study. The total percent of current 
smokers in the HRT group was 50.3% and 54.5% for non-users.15 These two 
characteristics were not separated or discussed in the overall results of mortality. These 
characteristics are also a known component by themselves to increase mortality and could 
influence overall results. 
The original study was conducted for bone loss and not for symptoms of 
menopause. 15 The observational section of these subjects was conducted many years later 
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and may not be adequate in that the original participation for these women was selected 
for other reasons than coronary heart mortality reduction.15 
A similar observation study conducted by Shlipak et al,16,followed 
postmenopausal women who had a diagnosis of an MI and observed for in-patient 
survival or mortality in the hospital in one of 1674 participating hospitals.16 There was no 
record of menopausal information about the women and they selected an age of ≥ 55 
years of age with the hopes that most women would be postmenopausal. Hormone users 
in this group were more likely to be white and less likely to have a history of diabetes, 
heart failure, prior MI, and prior stroke than nonusers but were more likely to have 
hypercholesteremia and family history of premature coronary artery disease and to use 
tobacco.16 There is likely much bias that came from the results based on this information 
including race and past medical history.  
It is important to highlight that the study also states that HRT users received more 
aggressive in-hospital care than women of non-users.16 This could potentially be multi-
factorial, but also due in part of race. The last limitation of this study is that there was no 
information for the duration of use that each woman used HRT or the dosage level. This 
could make the total outcome very variable among users after an MI. The study did 
control for women being healthier in the HRT user group compared to the non-user group 
and did still in fact find that HRT did prove that in-hospital mortality was lower 
compared to non-users.   
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CONCLUSION  
Coronary heart disease remains the number one killer of women,1,and this has 
been found to increase with age. Women who experience decreased quality of life from 
menopause seek HRT to ease their symptoms, but are faced with the challenges of 
assessing risks and benefits. Even for providers, the literature is unclear as to how exactly 
HRT affects postmenopausal patients when assessing for risks associated with CHD and 
mortality. In can be concluded that treatment decisions concerning hormone replacement 
must be made on an individual basis, taking into account the age of the woman, the 
degree of the bothersome postmenopausal symptoms, and any associated disease risk 
factors. 
Efficacy  
It would appear that HRT is effective and as safe as any other therapeutic option 
for the prevention of CHD that leads to mortality in postmenopausal women, provided 
the treatment is started at an appropriate time when a woman has ceased menstruation 
and is symptomatic with a suitable dose.  Stopping smoking, addressing obesity, 
increasing exercise and addressing diet issues are all key steps to reducing CHD events 
that may ultimately lead to an end result of mortality. However, these preventative 
measures are not enough. Based on the studies discussed, it can be concluded that women 
who are symptomatic from menopause and do not have a history of coronary heart 
disease or breast cancer would benefit from HRT as soon as menopause starts and 
experience reduced mortality from CHD events if taken for 2-3 years minimally. 
Certainly, to make a more defined time period for benefit, more studies are needed.  
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Future Studies 
Further studies are needed to establish what types and doses of HRT are optimal 
for preventing mortality from CHD. In addition, larger-scale, placebo controlled, long-
term prospective studies, which carefully analyze the benefit/harm ratio will aid in 
determining HRT’s wide spread use.3 Large randomized trials of long duration, studying 
younger women near the start of menopause, would be needed to adequately address the 
correct duration of HRT use.  In a perfect world, there would be a large enough 
population with mixed diversity and no known CHD placed in a study in which women 
are divided into groups that take HRT and those that do not. All these women would take 
the same dose and be non-smokers. In addition to this, these women would be 
subcategorized based off of BMI. At the end of the study, women should be selected to 
be in different duration categories and followed long-term until mortality is reached. 
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TABLES 
Table1. Matrix of Reviewed Literature 
Study/Design  Population Comparison Outcomes Comments 
Rossouw et al13  
(2002) 
Prospective case-control 
  
16 025 postmenopausal 
women 
 
 
 
HRT vs 
placebo 
Trial stopped due 
to risks of HRT 
outweighing 
benefits 
 
Multiple flaws 
in study 
Rossouw et al9  
(2007) 
Retrospective case-contol 
Decreased 
mortality with 
women aged 50-
59 
Hedblad et al14  
(2002) 
Retrospective Cohort 
5 862 postmenopausal 
women 
HRT vs non 
use 
All cause 
mortality 
Good study. 
No information 
about dosing.  
Alexandersen et al15                  
(2006) 
Retrospective cohort 
1 458 postmenopausal 
women 
HRT vs 
nonuse 
All cause 
mortality 
Originally used 
for 
preventative 
bone loss.  
Shlipak et al16  
(2001) 
Retrospective cohort 
114 724 postmenopausal 
women 
HRT vs non 
use 
Mortality Good 
randomization. 
Limitations did 
not include 
prior use of 
HRT 
Barrett-Connor & Laughlin1 
(2005) 
Retrospective cohort 
204 postmenopausal women HRT  use vs 
past HRT 
use vs non-
use 
Coronary Artery 
Calcium Score 
Small 
observational 
study that was 
limited to 
CACS and not 
mortality 
Özdemir et al3   
(2004) 
Prospective cohort 
36 postmenopausal women  Non use 
HRT at 
baseline vs 
HRT at 3 
and then 
again at 6 
months 
Pulse wave 
Doppler 
echocardiography 
and symptom-
limited exercise 
stress test 
Small study. 
Only examined 
diagnostic tests 
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Table 2: Baseline Characteristics of the WHI Estrogen Plus Progestin Trial13  
Characteristics HRT  
(n=8506) 
Placebo  
(n=8102) 
Years Since Menopause 
<10 
(n=5494) 
10-19 
(n=6041) 
≥20 
(n=3653) 
Age group at 
screening (years) 
50-59 2839 (33.4%) 2683 (33.1%) 4092 
(74.5%) 
831 
(13.8%) 
55 
(1.5%) 
60-69 3853 (45.3%) 3657 (45.1%) 1402 
(25.5%) 
4320 
(71.5%) 
1145 
(31.3%) 
70-79 1814 (21.3%) 1762 (21.7%) 0 890 
(14.7%) 
2453 
(76.2%) 
Race/Ethnicity White 7140 (83.9%) 6805 (84.0%)  
Black 549 (6.5%) 575 (7.1%) 
Hispanic 472 (5.5%) 416 (5.1%) 
American 
Indian 
26 (0.3%) 30 (0.4%) 
Asian/Pacific 
Islander 
194 (2.3%) 169 (2.1%) 
Unknown 125 (1.5%) 107 (1.3%) 
Body Mass Index 
(BMI) 
<25 2579 (30.4%) 2479 (30.8%) 
25-29 2992 (35.3%) 2834 (35.2%) 
≥30 2899 (34.2%) 2737 (34.0%) 
Smoking Status Never 4178 (49.6%) 3999 (50.0%) 
Past 3362 (39.9%) 3157 (39.5%) 
Current 880 (10.5%) 838 (10.5%) 
 
Table 3: Clinical Outcomes of the WHI13 
Events HRT 
(n=8506) 
Placebo  
(n=8102) 
Statistical Information 
(HR, CI) 
Total Death 231 (0.52%) 218 (0.53%) HR 0.98, CI 0.70-1.37 
CHD Death 33 (0.07%) 26 (0.06) HR 1.18, CI 0.70-1.97 
CHD Events 164 (0.37%) 122 (0.30%) HR 1.29, CI 1.02-1.63 
 
Table 4: Secondary Analysis of Results By Age at Baseline of the WHI9 
 Age Group at Randomization 
 50-59 yrs 60-69yrs 70-79 yrs 
 HRT  
(n=4476) 
Placebo 
(n=1673) 
HR, 
CI 
HRT 
(n=6240) 
Placebo 
(n=6122) 
HR, 
CI 
HRT 
(n=3100) 
Placebo 
(n=3053) 
HR, 
CI 
Total 
Mortality 
35 47 0.69, 
0.44-
1.07 
111 94 1.09, 
0.83-
1.44 
103 95 1.06, 
0.80-
1.41 
CHD 
events 
38 27 1.29, 
0.79-
2.12 
78 72 1.03, 
0.74-
1.43 
79 54 1.48, 
1.04-
2.11 
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Table 5: Secondary Analysis of WHI Results By Years Since Menopause at 
Baseline9 
 Years since Menopause 
 <10 10-19 ≥20 
HRT 
(n=2782) 
Placebo 
(n=2712) 
HR, CI HRT 
(n=3074) 
Placebo 
(n=2994) 
HR, CI HRT 
(n=1850) 
Placebo 
(n=180
3) 
HR, 
CI 
Total 
Mortality 
39 46 0.81, 
0.52-
1.24 
79 79 1.03, 
0.75-
1.41 
98 88 1.11, 
0.83-
1.49 
CHD 
events 
31 35 0.88, 
0.54-
1.43 
66 53 1.23, 
0.85-
1.77 
77 47 1.66, 
1.14-
2.41 
 
Table 6: Baseline Characteristics in Observational Studies 
Studies Hedblad et al14 Alexandersen et al15 Shlipak et al16 
 HRT 
(n=962) 
Non-
User 
(n=4759) 
 HRT 
(n=533)  
Placebo 
(n=727) 
HRT 
(n=7353) 
Non-User 
(n=107 
371) 
Age Range 
(Average of 
yrs and %) 
 
50-57 
(53.8 
+/- 3.1) 
51-57 
(54.1 +/- 
3.0) 
 44-75 
(55.3 
+/- 5.6) 
44-75 
(55.9 +/- 6.4) 
55-64 2353 
(32%) 
15 032 
(14%) 
   65-74 2647 
(36%) 
28 990 
(27%) 
   75-84 1912 
(26%) 
38 654 
(36%) 
   >84 515 
(7%) 
24 695 
(23%) 
BMI 
(Average 
and %) 
<26 718 
(74.7%) 
3055 
(64.2%) 
21-29 
(24.9 
+/- 3.9) 
21-30 
(25.6 +/- 4.5) 
n/a 
26-30 176 
(18.3%) 
1075 
(22.6%) 
>30 67  
(7%) 
623 
(13.1%) 
Missing 
Values 
1  
(0.1%) 
48 
(0.1%) 
Smoking: 
Current 
(%) 
Never 441  
(45.8%) 
2261 
(47.5%) 
278 
(50.3%) 
396 
(54.5%) 
1544  
(21%) 
15032 
(14%) 
Former  205 
(21.4%) 
441 
(19.5%) 
Current 315 
(32.7%) 
746 
(33%) 
Race n/a n/a White 6691 
(91%) 
91265 
(85%) 
Black 294  
(5%) 
8590 
(8%) 
Other  386 
(5%) 
7516 
(7%) 
Education 
Level 
(Secondary) 
164 (17%) 557 (11.7%) n/a n/a 
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Table 7: Results of Observational Studies 
Studies Alexandersen et al15 Shlipak et al16 Hedblad et al14 
 HRT + 
(n=533) 
Placebo 
(n=727) 
HRT 
(n=962) 
Non-Users 
(n=4759) 
Statistical  
Relevance 
Statistical 
Relevance 
HRT 
(n=7353) 
Non-Users 
(n=107 371) 
Statistical 
Relevance 
All-
Cause 
Mortality 
51 
(29.3%) 
123 
(70.7%) 
30 172 RR 0.29,  
CI 0.12-0.71; 
p=0.007 
 
n/a 514 (7%) 17 179  
(16%) 
OR 0.40,  
CI 0.36-0.43 
CHD 
Mortality 
(n= and 
%) 
8  
(20.5%) 
31 
(79.5%) 
5 
 
92 Mortality 
 rate 0.36 for 
HRT (CI 0.08-
1.08) and 1.10 
in non-users 
(CI 0.78-1.41) 
per 1000 
person-years 
HR 0.47, CI 
0.21-1.03; 
p=0.062 
Age  
55-64 
(2332) 
70 
 (3%) 
Age  
55-64 
(n=15 385) 
1385  
(9%) 
OR 0.33,  
CI 0.26-0.42 
   Age  
65-74 
(2620) 
183 
 (7%) 
Age 65-74 
(n=28 584) 
3716  
(13%) 
OR 0.51,  
CI 0.44-0.60 
   Age  
75-84  
(1879) 
188  
(10%) 
Age 75-84 
(n=38 962) 
7013  
(18%) 
OR 0.50, 
CI 0.43-0.58 
   Age 
>85 
(522) 
78  
(15%) 
Age >85 
(n=24 440) 
5377  
(22%) 
OR 0.63,  
CI 0.50-0.81 
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